Commercially Available Cannabis Products for Immune Support
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05944705 |
Recruitment Status :
Recruiting
First Posted : July 13, 2023
Last Update Posted : February 29, 2024
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | February 20, 2023 | ||||
First Posted Date | July 13, 2023 | ||||
Last Update Posted Date | February 29, 2024 | ||||
Actual Study Start Date | November 1, 2023 | ||||
Estimated Primary Completion Date | November 1, 2024 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Adverse Events and Serious Adverse Eventss [ Time Frame: To Study Completion, approximately 30 days ] Evaluate the safety of commercially available hemp and cannabis products marketed for immune support through assessment of AEs and SAEs. AEs and SAEs will also be collected for the non-user group
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Commercially Available Cannabis Products for Immune Support | ||||
Official Title | Commercially Available Cannabis (Hemp) Products for Immune Support: A Prospective Observational Study to Evaluate Safety and Effects | ||||
Brief Summary | This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support. | ||||
Detailed Description | In the era of COVID-19, there has been much speculation about the risks and benefits of cannabis use for immune support. It is well known that the endocannabinoid system plays a role in the regulation of the immune response and its role in inflammation reduction may be useful in terms of a potential adjunctive therapy for acute infection. Cannabis products vary widely in their composition and may have a varying effect based on the strain and the associated terpenes. Here, we aim to track cannabis and hemp usage during an acute infection to understand it's safety and effects in a symptomatic population. Given the fast and widespread acceptance and use of cannabis products in the US market, commercial use has outpaced randomized controlled trials (RCTs). Thus, carefully designed observational studies are important to understand how these products are affecting consumers. Prospective observational designs allow for real-world examinations of commercialized products with similar effect sizes to RCTs. Although observational designs have some drawbacks, a review covering 1,583 meta-analyses across 228 medical conditions compared the effect sizes from RCTs with those from observational studies for the same medical conditions and found no differences between the two. (1) These data provide evidence that a carefully designed observational study can help us better understand the effects of commonly used products such as cannabis edibles. The aim of this observational study is to evaluate the safety and associated effects of commercially available cannabis products in the US in symptomatic individuals seeking them for immune support. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Individuals who are suffering an acute illness | ||||
Condition |
|
||||
Intervention | Dietary Supplement: Immune Support Supplement
Cannabinoid and co-active emulsion
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
200 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | December 1, 2024 | ||||
Estimated Primary Completion Date | November 1, 2024 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT05944705 | ||||
Other Study ID Numbers | CannabisforImmuneSupport | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Current Responsible Party | Center For Interventional Pain and Spine | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor | Center For Interventional Pain and Spine | ||||
Original Study Sponsor | Same as current | ||||
Collaborators | Agronomed LLC | ||||
Investigators |
|
||||
PRS Account | Center For Interventional Pain and Spine | ||||
Verification Date | February 2024 |